Intervet Chile launch two new vaccines

4 November 2004

Intervet first entered the Chilean aquatic animal health market in 2000 with the monovalent vaccine against IPN, Compact™ IPN, protecting against infectious pancreatic necrosis virus. Due to the excellent results obtained in a large number of Chilean salmon farming companies, sales of this vaccine increased 10 fold in four years. 

Today in Chile, almost all Atlantic salmon, along with a growing percentage of trout, are vaccinated against several pathogens of longstanding importance, like IPN. However, during the last few years, the Chilean aquaculture industry has experienced the appearance of new pathogens like atypical Aeromonas salmonicida (causing furunculosis) and Vibrio ordalii. This latter bacterial pathogen was first isolated and identified in 2003, by Intervet scientists in Norway and Chile, in active collaboration with ADL Diagnostic Chile Ltda. (one of the main aquatic animal health diagnostic laboratories). It is now clear that this is the causative agent of vibriosis in Atlantic salmon in Chile (see Intervet AAH Newsletter no. 8). Both these new diseases are characterized by their aggressiveness and their ability to inflict serious economic losses for producers, which are manifested by high mortality levels coupled to a drop in quality of the final product.  
 
In recent months, two new Intervet vaccines have been launched in the Chilean aquatic animal health market, namely, Compact™ FurIPN (a bivalent vaccine against furunculosis and IPN) and Compact™ VibIPN (a bivalent vaccine against vibriosis and IPN). These vaccines provide excellent protection against IPN and the two new pathogens. With the introduction of these new products, Intervet continues to be a major contributor to the increasing productive efficiency of the Chilean aquaculture industry.